GlassScriptPhysician profile
Daniel A Panfil
NPI 1972679264
$689.27
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $544 · 2022: $145.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $210.38 | 2021-2022 | |
| Abbvie INC. | $173.24 | 2021 | |
| Sunovion Pharmaceuticals INC. | $70.07 | 2021 | |
| Jazz Pharmaceuticals INC. | $50.27 | 2021-2022 | |
| Lundbeck LLC | $45.25 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $40.55 | 2021-2022 | |
| Alkermes, INC. | $37.84 | 2021-2022 | |
| Eisai INC. | $33.34 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.88 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.45 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Panfil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.